MVST SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Microvast (MVST) Investors of Securities Class Action Lawsuit Deadline on September 21, 2026

Microvast faces a proposed securities class action alleging it overstated margin prospects and the timing of its Huzhou Phase 3.2 expansion; investors who bought shares between April 1, 2025 and March 16, 2026 may participate. The key corrective disclosure was Q4 2025 results: revenue fell 15% year over year to $96.5 million versus $136.4 million consensus, while gross margin collapsed to about 1% from 36%, prompting a 34.2% one-day share-price decline to $1.52 on March 17, 2026. Earlier disclosures tied to a short-seller report, CFO departure, and expansion delay each triggered roughly 10% declines.

Analysis

This is not a fresh operating disclosure; it is plaintiff-lawyer solicitation built on already public events, so the near-term incremental information content is low. The relevant investable signal is that the latest impairment and revenue miss transform the debate from execution timing into inventory quality and demand visibility. A near-zero gross-margin quarter implies that working-capital conversion, covenant headroom, and future capital needs matter more than nominal installed capacity over the next 1-3 quarters.

The most damaging second-order effect is commercial credibility: delayed customer programs can create a feedback loop in which OEMs defer qualification and orders, worsening factory utilization and forcing further absorption-related margin pressure. The CFO turnover and short-seller allegations increase the discount investors apply to management guidance; even a production start at Huzhou would not by itself restore a growth multiple without independently observable shipment, utilization, and cash-flow evidence. Better-capitalized battery incumbents, particularly CATL-linked supply chains and established automotive-cell vendors, gain negotiating leverage when a smaller supplier's delivery credibility weakens.

The September 21 lead-plaintiff deadline is primarily a headline/liquidity catalyst rather than a fundamental one. The 6-18 month risk is dilution or additional asset/inventory write-downs if specialized ESS demand does not recover, while the upside case requires sequential gross-margin normalization, receivables/inventory reduction, and confirmed customer launches. A sharp reversal is possible in a low-priced, likely high-short-interest equity, but it would require evidence that the impairment was discrete rather than recurring—not another capacity or partnership announcement.

Key Decisions for Investors

• Maintain/establish a small short MVST only on borrow availability and liquidity confirmation; use a 1-3 month horizon around the next earnings update. Target is a further de-rating if gross margin remains below 10% or inventory rises; cover on verified sequential margin recovery above 15% plus positive operating-cash-flow inflection.
• Do not treat the litigation deadline as a standalone short catalyst: it is largely non-fundamental and may produce a reflexive squeeze. Size any short for gap risk and use a hard risk trigger of a sustained move above the post-earnings reaction range accompanied by disclosed customer shipment data.
• For EV/battery exposure, prefer avoiding broad shorts such as KARS or LIT: the company-specific distress is unlikely to transmit materially to diversified battery leaders. Monitor instead for disclosed customer program cancellations or supplier substitutions, which would create a cleaner relative-value opportunity against more exposed peers.
• Set an alert for the next filing: inventory balance, impairment reversals/additions, receivables days, capex commitments, and financing terms are the decisive data. Absent those disclosures, there is no high-conviction long despite the magnitude of the decline.